BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BT-5528’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-5528 is under development for the treatment of advanced solid tumors including gastric cancer, ovarian cancer, esophageal cancer, triple-negative breast cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, bladder cancer, pancreatic cancer and urothelial cancer. It acts by targeting cells expressing ephrin type-A receptor 2 (Epha2). The drug candidate is a bicycle toxin conjugate comprises of bicyclic peptide conjugated to toxin-linker with payload (vc-PABC-MMAE). It is developed based on bicyclic peptide technology and is administered through intravenous route. It was under development for the treatment of prostate cancer.
Bicycle Therapeutics overview
Bicycle Therapeutics is a biotechnology company. It develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company’s Bicycle conjugates include BT1718, BT5528, and BT8009; and Immuno-Oncology offers BT7480, BT7401, and BT7455. Bicycle Therapeutics proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to identify bicycles that provide antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. The company operates with other biotechnology companies for the development of bicyclic peptide inhibitors for the treatment of ophthalmic diseases such as diabetic macular edema, renal elimination, versatility for multimerization and conjugation. It works in collaboration with Cancer Research UK(CRUK), AstraZeneca Plc in the areas of oncology, respiratory, cardiovascular, and metabolic diseases, among others. The company has operations in Massachusetts, the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of BT-5528’s drug-specific PTSR and LoA scores, buy the report here.